Why we don't do parallel import.

Parallel import is a legitimate practice in large parts of the pharmaceutical market. It is worth saying that plainly at the start of this page, because the goal here is not to argue that parallel import is illegitimate. The goal is to explain why Reserve Meds does not operate through parallel import channels, and why our operating posture is built around a different mechanism: the named-patient pathway, with a single-origin US supply chain.

What parallel import is

Parallel import, in its technical form, is the movement of already-marketed pharmaceutical product between two authorized markets without the involvement of the manufacturer. A product authorized for sale in one European Union member state, for example, can be purchased by a licensed wholesaler, repackaged or relabeled to meet the requirements of a different EU member state, and sold into that second market. The practice is legal within the EU and in a number of other jurisdictions, and it exists to create price competition and supply resilience within regulatory environments designed to permit it.

What the named-patient pathway is, by contrast

The named-patient pathway is different in its foundational mechanic. It moves a specific unit of medicine, from its original authorized source, to a specific identified patient in a country where the medicine is not registered or not locally available, under an authorization that is specific to the drug, the indication, and the patient. The product is not being imported for resale and is not being inserted into the destination's general pharmacy market; it is being imported for one named patient under a documented clinical and regulatory framework.

Why the two pathways are structurally different

Three structural differences matter in practice. First, the authorization basis. A parallel-import shipment moves under the general market authorization of the destination country; a named-patient shipment moves under a case-specific authorization issued by the destination's health authority for one patient. Second, the chain of custody. A parallel-import shipment typically passes through one or more intermediate wholesalers that may repackage or relabel the unit, which interrupts the manufacturer-to-patient traceability that serialization frameworks are designed to create; a named-patient shipment through our pipeline moves under the DSCSA-serialized transaction records from US wholesaler to Altima Care to patient without intermediate repackaging. Third, the regulatory posture at destination. A parallel-import shipment is handled by the destination's general pharmacy market regulation; a named-patient shipment is handled under the destination's specific NPP framework, which applies different documentation and pharmacovigilance requirements.

What we operate, concretely

Reserve Meds moves US-authorized product from US specialty wholesalers to patients in destination countries under named-patient authorizations. The source is US-authorized and US-sourced; the chain is DSCSA-serialized; the dispensing is performed by Altima Care, a US-licensed specialty wholesaler; the destination authorization is specific to the patient, the drug, and the indication; the documentation package travels with the unit; the product is not repackaged or relabeled between manufacturer and patient except as the manufacturer's own labeling provides. This structure is what our regulatory, clinical, and sourcing posture is built around.

Why we chose this structure

Three reasons. The first is traceability. A specialty biologic that has been repackaged or relabeled in transit cannot be traced to manufacturer lot and serial number with the same integrity as a unit that has moved through a single DSCSA-serialized chain. For the prescribers we work with, that matters, because the prescriber's professional exposure is meaningfully different depending on whether the product the patient received can be traced cleanly. The second is authenticity. Parallel-import channels, even legal ones, present a wider surface area for counterfeit substitution than a single-origin manufacturer-authorized chain. Serialized US specialty wholesale channels and a US-licensed dispensing pharmacy reduce that surface area to something we are prepared to underwrite. The third is regulatory posture. The named-patient pathway, operated through a single-origin supply, is the framework the destination regulators we work with have built their NPP frameworks around. A coordinator that tries to bolt parallel-import mechanics onto an NPP framework ends up in a category mismatch that neither the regulator nor the prescriber is comfortable with.

What we gain by saying no to parallel import

We gain simpler documentation. Every case we coordinate looks the same at the chain-of-custody level: US manufacturer, US wholesaler, US specialty pharmacy, licensed broker at destination, receiving institution, patient. That uniformity makes our clinical and regulatory review faster and our pharmacovigilance reporting cleaner. We gain easier prescriber conversations. A treating physician outside the US, deciding whether to take on a cross-border case, can evaluate our supply chain in one diagram rather than several. We gain a tighter compliance surface. Our compliance and insurance posture, our pharmacy licensure, our wholesaler licenses, and our DSCSA attestations all cohere around a single operating model. And we gain a clearer brand promise to families: the product that arrives is the product the manufacturer shipped, carrying the manufacturer's original labeling, through a chain that has not been interrupted.

What we lose

We lose a cost lever. Parallel-import channels can be lower-cost than manufacturer-authorized US channels for a subset of therapies at a subset of moments. Coordinators that operate through parallel import can sometimes beat our price for a given case. We accept that trade. The families and institutions we serve are not optimizing first for the lowest nominal price; they are optimizing for the tightest chain of custody, the most defensible regulatory posture, and the most transparent documentation. Where a family is optimizing for a lower nominal price and is willing to accept a different chain-of-custody posture, they have other coordinators to choose from, and the honest comparison is the one we set out on the comparison page.

What we are not saying

We are not saying that parallel import is illegal. In most jurisdictions it is lawful and regulated. We are not saying that other coordinators operating through parallel import are acting in bad faith. Many operate professionally within the rules of the jurisdictions where they work. We are not saying that every unit moving through a parallel-import channel is suspect. The overwhelming majority are authentic. What we are saying is that our service is positioned for cases where traceability, authenticity assurance, and a single-origin US-authorized chain are the load-bearing attributes, and that the named-patient pathway operated through that chain is the mechanism we have chosen to deliver on those attributes. That posture is why we do not do parallel import, and it is the shape of what we offer in its place.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.